Figure 9
Prognosis-predicted nomograms and inner validation for 1, 3, and 5 years in the GSE14520 cohort. (A-–B): Overall survival predicting nomogram using tumor size, cirrhosis, BCLC stage, AFP levels, APOL3 and APOL6 expression for 1, 3, and 5 years and inner validation for 1, 3, and 5 years. (C–D): Recurrence-free survival predicting nomogram using sex, cirrhosis, BCLC stage APOL2, APOL3 and APOL6 expression and inner validation for 1, 3, and 5 years for 1, 3, and 5 years.
